Wells Fargo & Company MN Increases Stake in Replimune Group, Inc. (NASDAQ:REPL)

Wells Fargo & Company MN boosted its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 102.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 77,371 shares of the company's stock after purchasing an additional 39,121 shares during the period. Wells Fargo & Company MN owned 0.11% of Replimune Group worth $937,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in REPL. China Universal Asset Management Co. Ltd. grew its stake in shares of Replimune Group by 24.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock valued at $198,000 after buying an additional 3,177 shares during the period. SG Americas Securities LLC lifted its stake in Replimune Group by 14.7% during the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company's stock valued at $318,000 after acquiring an additional 3,374 shares in the last quarter. Rhumbline Advisers grew its position in Replimune Group by 8.3% in the 4th quarter. Rhumbline Advisers now owns 95,465 shares of the company's stock worth $1,156,000 after purchasing an additional 7,317 shares in the last quarter. JPMorgan Chase & Co. raised its position in Replimune Group by 3.3% in the third quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company's stock worth $2,733,000 after acquiring an additional 8,074 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in Replimune Group by 7.3% in the fourth quarter. Bank of New York Mellon Corp now owns 174,518 shares of the company's stock valued at $2,113,000 after acquiring an additional 11,893 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Trading Down 1.3 %

Shares of NASDAQ REPL traded down $0.13 during trading hours on Monday, hitting $9.88. The company's stock had a trading volume of 60,789 shares, compared to its average volume of 777,170. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The stock has a market cap of $760.75 million, a price-to-earnings ratio of -3.22 and a beta of 0.68. The business has a 50-day simple moving average of $9.81 and a 200-day simple moving average of $11.61. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). On average, analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on REPL shares. HC Wainwright lifted their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. BMO Capital Markets lifted their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. increased their target price on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Replimune Group currently has a consensus rating of "Buy" and an average price target of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.